41st week of 2019 patent applcation highlights part 9 |
Patent application number | Title | Published |
20190307857 | MODIFIED mRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF - The invention relates to methods and compositions for treating a UDP glucuronosyltransferase family 1 deficiency based on mRNA therapy. | 2019-10-10 |
20190307858 | Vasoconstrictive and Antibacterial Combination Treatment for Rosacea - The invention relates to the field of medicine, specifically to the field of treatment of rosacea. The invention relates to a novel composition and a novel kit of parts, both comprising a vasoconstrictive compound and a compound specifically targeting a bacterial cell, preferably a gram positive bacterial cell. The invention further relates to said composition and/or kit of parts for medical use, preferably for treating an individual suffering from rosacea. | 2019-10-10 |
20190307859 | ENZYME-RICH MALT EXTRACT (ERME) FORMULATIONS - The present invention relates to compositions comprising: malt extract including a plurality of enzymatically active enzymes including at least fructanase and amylase; one or more medium-chain triglycerides (MCTs) and/or at least one biologically acceptable metal component and use of those compositions as veterinary and human medicaments | 2019-10-10 |
20190307860 | LATIGLUTENASE (ALV003) FOR USE IN THE TREATMENT OF SYMPTOMATIC CELIAC DISEASE, GLUTEN INTOLERANCE OR GLUTEN SENSITIVITY - A method is provided for reducing the severity and/or frequency of symptoms or clinical manifestations resulting from gluten ingestion by administering to a seropositive patient with symptomatic celiac disease, gluten intolerance, or gluten sensitivity latiglutenase (ALV003) in an amount from about 100 mg to about 1200 mg per day. | 2019-10-10 |
20190307861 | METHOD FOR PROMOTING EXPRESSION OF INSULIN RECEPTOR SUBSTRATE-2 - The present invention relates to a method for promoting expression of insulin receptor substrate-2, comprising administering an effective amount of plasminogen to a subject; furthermore, the present invention relates to a medicament for promoting expression of insulin receptor substrate-2. | 2019-10-10 |
20190307862 | SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa - The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent. | 2019-10-10 |
20190307863 | ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF - The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle. | 2019-10-10 |
20190307864 | ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF - The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle. | 2019-10-10 |
20190307865 | METHODS FOR TREATMENT OF AND PROPHYLAXIS AGAINST INFLAMMATORY DISORDERS - An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual. | 2019-10-10 |
20190307866 | ANTINECROTIC ACTIVITY OF ALPHA 1-ANTITRYPSIN - The present invention is related to the use of alpha-1-antitrypsin as an anti-necrotic agent. This invention provides a method for the treatment of tissue necrosis by administration of alpha-1-antitrypsin. This invention further provides methods for prophylactic treatment of tissue necrosis and for inhibition of tissue necrosis in culture by addition of alpha-1-antitrypsin. | 2019-10-10 |
20190307867 | ANTI-ABETA THERAPEUTIC VACCINES - A liposomal vaccine composition comprises a β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided. | 2019-10-10 |
20190307868 | NEOANTIGENS AND METHODS OF THEIR USE - The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer. | 2019-10-10 |
20190307869 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER USING BACTERIA - Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde. | 2019-10-10 |
20190307870 | SYNTHETIC MALARIA IMMUNOGENS, COMBINATIONS THEREOF, AND THEIR USE TO PREVENT AND TREAT MALARIA INFECTIONS - Provided herein are sequences of | 2019-10-10 |
20190307871 | A MULTI-EPITOPE DNA VACCINE FOR HEARTWATER - Nucleic acids include sequences encoding | 2019-10-10 |
20190307872 | NOVEL METHOD FOR PREVENTING OR TREATING M TUBERCULOSIS INFECTION - The present invention is directed to methods of preventing reactivation of active and latent | 2019-10-10 |
20190307873 | NOVEL PNEUMOCOCCAL VACCINE FORMULATIONS - Immunogenic composition are provided comprising PnCo and/or GlpO polypeptides identified as being preferentially expressed during the virulent phase of an infection related to streptococcal bacteria. The compositions can be used for eliciting immune response against streptococcal infections, such as against infections caused by | 2019-10-10 |
20190307874 | MENINGOCOCCAL INFECTION AND MODIFIED NEISSERIA LACTAMICA - The invention relates to a modified | 2019-10-10 |
20190307875 | IMMUNOGENIC COMPOSITION COMPRISING CYAA-DERIVED POLYPEPTIDE PROMOTING A TH1/TH17-ORIENTED IMMUNE RESPONSE - The invention relates to the use of a polypeptide derived from the adenylate cyclase of a | 2019-10-10 |
20190307876 | MULTIVALENT RECOMBINANT SPV - The present invention relates to novel recombinant swinepox viruses and their use in vaccine compositions. The recombinant swinepox viruses of the invention are doubly defective for IL18bp and TK genes, and comprise at least one foreign gene cloned into defective TK gene sequence. The invention is particularly suited to produce swine vaccines, particularly for vaccinating swine against PCV2 infection. | 2019-10-10 |
20190307877 | COMPOSITIONS AND METHODS FOR VACCINATION AGAINST INFLUENZA - Described herein are methods and compositions for vaccination against influenza. The compositions comprise recombinant engineered influenza hemagglutinin polypeptides. Also disclosed are methods of producing recombinant engineered influenza hemagglutinin polypeptides in cell-based systems. | 2019-10-10 |
20190307878 | IMMUNE COMPLEX - The present invention relates to immunogenic immune complexes, related compositions, and related methods. | 2019-10-10 |
20190307879 | ADENOVIRUS-VECTORED MULTIVALENT VACCINE - The invention pertains to a vaccine comprising an immunologically effective amount of a novel live-vectored multivalent vaccine formulation that affords immunization to multiple antigens of a pathogen that is relatively impervious to vaccine development by providing multiple virus-expressed antigens and a pharmaceutically acceptable carrier and/or an adjuvant. Further, a method of immunizing a subject against an exposure to a pathogen that is relatively impervious to vaccine development is provided, wherein the method comprising the steps of administering the vaccine to a subject to induce an immune response against antigenic proteins or fragments thereof. | 2019-10-10 |
20190307880 | METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS - The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof). | 2019-10-10 |
20190307881 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2019-10-10 |
20190307882 | SOMATIC OPSINS FOR SINGLE CELL RESOLUTION OPTOGENETICS - The invention, in some aspects, relates to polypeptide molecules and their encoding nucleic acid molecules and use of such molecules to target opsins to the soma of cells in which they are expressed. Compositions of the invention may be delivered to cells and subjects and used in methods to modulate electrical activity of cells in which they are expressed, and for treatment of diseases and conditions in subjects. | 2019-10-10 |
20190307883 | CELL PENETRATING NUCLEOLYTIC ANTIBODY BASED CANCER THERAPY - Cancer cells with defects in DNA repair are highly susceptible to DNA-damaging agents, but delivery of therapeutic agents into cell nuclei can be challenging. A sub-set of autoantibodies having nucleolytic activity are capable of nuclear penetration. These antibodies can be used as therapeutic agents targeted towards DNA repair-deficient malignancies. | 2019-10-10 |
20190307884 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2019-10-10 |
20190307885 | SELF-ASSEMBLED GELS FOR CONTROLLED DELIVERY OF BIOLOGICS AND METHODS OF MAKING THEREOF - Gels are formed based on generally recognized as safe (GRAS) low molecular weight amphiphilic molecules in a self-assembly process. Therapeutic or prophylactic agents, such as biological macromolecules, are loaded without exposure to temperatures and/or organic solvents which can degrade or destroy the biologic agents and/or their activity. The resulting self-assembled gel composition contains microstructures having pores and aqueous domains at their interior, rendering them permeable to hydrophilic and hydrophobic molecules. This permeability allows sequestration of the biological macromolecules. Once sequestered, the electrostatic, hydrophobic-hydrophobic etc. interactions between the biological macromolecules and the amphiphilic gelators keep the labile payload encapsulated with high stability until the microstructures are degraded. | 2019-10-10 |
20190307886 | A CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEIN - The present invention relates to co-amorphous form of a substance and a protein. The present invention also relates to pharmaceutical, cosmetic or veterinary compositions comprising the co-amorphous form as well as to methods for preparing and using the co-amorphous form. | 2019-10-10 |
20190307887 | Body Cavity Foams - The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents. | 2019-10-10 |
20190307888 | POLYPLEX DELIVERY SYSTEM FOR PROTEINS, NUCLEIC ACIDS AND PROTEIN/NUCLEIC ACID COMPLEXES - Provided herein are nanoplexes comprising a payload selected from a protein and/or a polynucleic acid; and a plurality of copolymers comprising a first copolymer that is poly(N,N′-bis(acryloyl)cystamine-poly(aminoalkyl)) (PBAP), a second copolymer that is poly(C | 2019-10-10 |
20190307889 | STAPLED ACID-SENSITIVE ENDOSOME DISRUPTING ALGINATES - An agent comprising:
| 2019-10-10 |
20190307890 | PYRROLOBENZODIAZEPINE CONJUGATES - A conjugate of formula (I):L-(D | 2019-10-10 |
20190307891 | COMPOSITIONS - There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-6R binding polypeptide. | 2019-10-10 |
20190307892 | TARGETED DRUG DELIVERY AND THERAPEUTIC METHODS USING APO-E MODIFIED LIPID NANOPARTICLES - Methods for targeted delivery of therapeutic agents to a target cell or tissue with lipid nanoparticles comprising ApoE3. In embodiments, the invention specifically relates to targeted delivery of anticancer drugs, antibiotics, antifungal drugs, and diagnostic contrast agents, and associated treatment and diagnostic methods. In embodiments, diseases/conditions treated include those associated with over-expression of LDL receptors. | 2019-10-10 |
20190307893 | NANOVESICLES WITH PORPHYRIN-LIPID CONJUGATE CORE - The application relates to liposomal nanovesicles comprising porphyrin-lipid conjugates within the liposomal lipid bilayer. Said porphyrin-lipid conjugate comprise porphyrins that are modified with a —CH(R | 2019-10-10 |
20190307894 | ENDOPLASMIC RETICULUM-TARGETING NANOVEHICLES AND METHODS FOR USE THEREOF - A method for treating a disease caused by protein retention in the endoplasmic reticulum (ER) with a sarcoplasmic/endoplasmic reticulum calcium ATPase pump inhibitor encapsulated in a polymer nanoparticle. The polymer nanoparticle is surface-modified such that it is targeted to the ER. The inhibitor reduces protein retention in the ER and the encapsulation lowers side effects of the inhibitor, e.g., cytotoxicity, as compared to administering the inhibitor without encapsulation. Also disclosed is a pharmaceutical composition that can be used for carrying out the method. Further provided is a transgenic mouse carrying in its genome a heterologous nucleic acid that encodes an H338Y mutant gp91 | 2019-10-10 |
20190307895 | PVP Coated Tellurium Nanorods with Antibacterial and Anticancer Properties - A nanoparticle formulation of tellurium nanorods. The tellurium nanoparticles are prepared using polyvinylpyrrolidone (PVP), which creates a functionalized coating on the outside of the particles. The nanorods have been shown to have antibacterial properties against both Gram-positive and Gram-negative bacteria, as well as anticancer properties when tested with human melanoma cells. | 2019-10-10 |
20190307896 | NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE - Provided herein are compositions, systems, kits, and methods for treating cancer in at least one bone of a subject using nanoparticles encapsulating, or conjugated to, an anti-cancer agent. In other embodiments, provided herein are composition, systems, kits, and methods for treating a bone disease (e.g., osteoporosis) in a subject using nanoparticle encapsulating, or conjugated to, a RANKL inhibitor. The nanoparticle are, in certain embodiments, neutral or nearly neutral in charge (e.g., zeta potential between −5 and +5 mV) and less than 250 nm in diameter on average (e.g. have an average diameter between 100 and 200 nm). | 2019-10-10 |
20190307897 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF - The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. | 2019-10-10 |
20190307898 | ADIPOCYTE-TARGETING NON-VIRAL GENE DELIVERY COMPLEX COMPRISING DUAL PLASMID VECTOR - The present disclosure relates to: an adipocyte-targeting non-viral gene delivery complex comprising a sh(FABP4+FABP5) dual plasmid vector; and treatment for obesity and obesity-induced metabolic syndromes by using the same and, more particularly, to a gene delivery complex comprising: an adipocyte-targeting sequence; a nine-arginine (R9) peptide; and a dual plasmid vector comprising a gene for treatment of obesity and obesity-induced metabolic syndromes, wherein the gene for treatment of obesity and obesity-induced metabolic syndromes is a base sequence inhibiting the expression of a FABP4 gene and a FABP5 gene. According to the present disclosure, in order to treat obesity-related diseases, a dual plasmid vector capable of simultaneously inhibiting the FABP4 and FABP5 genes is produced, and this vector is bound to a predetermined delivery system that specifically delivers the vector into adipocytes so as to provide a gene delivery complex. In this way, it is possible to achieve an excellent therapeutic effect on obesity which targets only adipocytes without cytotoxicity. | 2019-10-10 |
20190307899 | JUNCTOPHILIN-2 FRAGMENTS AND USES THEREFOR - Truncated junctophilin-2 related proteins, transcriptional repressor domains, vectors encoding the proteins or domains, and methods of using the proteins and domains, are provided. | 2019-10-10 |
20190307900 | COMPOSITIONS AND METHODS FOR TREATING MACULAR DYSTROPHY - The disclosure provides composition comprising a nucleic acid sequence comprising (a) a sequence encoding a vitelliform macular dystrophy-2 (VMD2) promoter, and (b) a sequence encoding a Bestrophin-1 (BEST1) protein as well as the use of these compositions for the treatment of macular dystrophy in a subject comprising administration of the composition to an eye of a subject via a subretinal or a suprachoroidal route. | 2019-10-10 |
20190307901 | METHOD FOR ENHANCED NUCLEIC ACID TRANSFECTION USING A PEPTIDE - A method for genetic transfection of mammalian cells is disclosed using a novel nanoparticle. The method comprises of mixing cationic peptides to nucleic acids, and then subsequently incorporating this mixture into a liposome with surface modification for transfection purposes and other medical application. With various types of cationic peptides envisioned, the method can be used for developing a nanoparticle comprising of either anionic or cationic liposomes, and for incorporating any type of nucleic acid. The medical application of this technology includes, but not limited to, gene therapy and nucleic acid based vaccination against a broad range of diseases, such as cancer and infectious disease. | 2019-10-10 |
20190307902 | NON-ALCOHOLIC FATTY LIVER REGULATOR 14-3-3 PROTEIN - The present invention relates to the 14-3-3 protein which is a non-alcoholic fatty liver regulating factor. According to the present invention, two isoform proteins of 14-3-3, i.e., 14-3-3β and 14-3-3γ, are different regulating factors for regulating the transcriptional activity of PPARγ | 2019-10-10 |
20190307903 | METHOD FOR MANUFACTURING A BIOCOMPATIBLE FLUID COMPRISING A POWDER OF MAGNETIC PARTICLES, BIOCOMPATIBLE FLUID COMPRISING A POWDER OF MAGNETIC PARTICLES - A method for manufacturing a biocompatible fluid including a powder of magnetic particles of elongated shape having a magnetic shape anisotropy and having a final granulometry, the final granulometry being defined by a first average size of the particles in a first direction and a second average size in a second direction different from the first direction, the final granulometry further being defined by a first distribution width of the first sizes and a second distribution width of the second sizes, the method including from a powder of magnetic particles having an initial granulometry different from the final granulometry, modification of the initial granulometry by milling and/or by sintering of the powder until the final granulometry is obtained; introduction of the powder of magnetic particles into a biocompatible fluid. | 2019-10-10 |
20190307904 | MODIFIED WOUND DRESSINGS - Embodiments described herein relate to compounds for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. Further embodiments relate to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic conversion of specific substrates which are contained in the compositions. Additional embodiments relate to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds. | 2019-10-10 |
20190307905 | Novel Polymer Derivatives, And Novel Polymer Derivative Imaging Probe Using Same - Provided are a block copolymer having an enhanced effect of imaging the interior of a tumor compared to known block copolymers and imaging probes using the known block copolymers; and an imaging probe using the block copolymer. Specifically, for the purpose of enhancing penetrability into a diseased target tissue and efficiently enhancing an imaging effect compared to known block copolymers and imaging probes using the known block copolymers, disclosed is a block copolymer in which a hydrophilic polymer segment containing a polyethylene glycol chain is linked to a hydrophobic polymer segment containing a polyamino acid chain having a signal group and optionally a hydrophobic substituent in a side chain, wherein the main chain polymer combining the polyethylene glycol chain and the polyamino acid chain has an average molecular weight of not less than 2 kDa and not more than 10 kDa, and the mass content percentage of the signal group and the optional hydrophobic substituent is not less than 5% by mass and not more than 50% by mass; and also disclosed is a composition including the block copolymer. | 2019-10-10 |
20190307906 | NOVEL ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT - The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment. | 2019-10-10 |
20190307907 | MOLECULAR SENSOR FOR NMR/MRI BASED ON ANALYTE-DEPENDENT SPECTRAL CHANGES OF TEMPORARILY ENCAPSULATED HYPERPOLARIZED 129XE - The present invention relates to a precursor of a molecular sensor for determining analyte concentrations and/or measuring analyte concentration changes comprising a host for an active nucleus, an NMR-modulating moiety and an interacting moiety, wherein said NMR-modulating moiety changes the resonance frequency or the chemical exchange saturation transfer (CEST) signal of the active nucleus-host complex, and wherein said interacting moiety specifically responds to an environmental parameter, to an analyte or to a target molecule that binds the analyte or said interacting moiety specifically binds to a target molecule in an analyte-dependent manner. The present invention further relates to a molecular sensor comprising an active nucleus and said precursor. The present invention further relates to a molecular sensor for determining analyte concentrations and/or measuring analyte concentration changes inside a cell, wherein moiety/ies of the sensor are expressed in said cells and then assembled inside said cell. The present invention further relates to uses of the molecular sensors as well as to an in vitro method for determining metal concentration and/or measuring metal concentration changes and a method for diagnosing and/or monitoring treatment of diseases causing changes in metal concentrations. | 2019-10-10 |
20190307908 | NANOEMULSION AGENTS FOR ULTRASOUND DIAGNOSTIC AND THERAPY - The present disclosure features, a kit, including a first compartment including a volatile fluorinated compound dissolved in a C | 2019-10-10 |
20190307909 | PRODUCTION OF 43SC RADIONUCLIDE AND ITS USE IN POSITRON EMISSION TOMOGRAPHY - The radionuclide 43Sc is produced at commercially significant yields and at specific activities and radionuclidic purities which are suitable for use in radiodiagnostic agents including imaging agents. In a method, a solid target having an isotopically enriched target layer prepared on an inert substrate is positioned in a specially configured target holder and irradiated with a charged-particle beam of protons or deuterons. The beam is generated using an accelerator such as a biomedical cyclotron at energies ranging from 3 to about 22. MeV. The method includes the use of three different nuclear reactions: a) irradiation of enriched 43Ca targets with protons to generate the radionuclide 43Scin the nuclear reaction 43Ca (p,n)43Sc, b) irradiation of enriched 42Ca targets with deuterons to generate the radionuclide 43Sc in the nuclear reaction 42Ca(d,n)43Sc, and c) irradiation of enriched 46Ti targets with protons to generate the radionuclide 43Sc in the nuclear reaction 46Ti (p,a) 43Sc. | 2019-10-10 |
20190307910 | STERILIZATION PROCESS CHALLENGE DEVICE - A sterilization process challenge device configured to test the efficacy of a sterilization process includes a tubular body for containing at least one sterilization indicator and a filter assembly including at least one filter member. The only flow path into the interior of the tubular body containing at least one sterilization indicator is provided through the filter assembly to control and restrict flow of a gaseous sterilization medium from an external environment. | 2019-10-10 |
20190307911 | STERILIZATION PROCESS CHALLENGE PACK - A sterilization process challenge pack including a base tray, a first cover, and a second cover is configured to provide a restrictive flow path for gaseous sterilization medium to test the efficacy of a sterilization process. The base tray includes at least one chamber containing a biological indicator and/or chemical indicator. The first cover including a notch is configured to cover the at least one chamber. The second cover is attached to peripheral surfaces of the base tray except at an unsealed portion. A flow path through the unsealed portion and the notch in the first cover provides the only fluid communication between an external environment and the at least one chamber. | 2019-10-10 |
20190307912 | FRAGRANCE DELIVERY DEVICE, SYSTEM, AND METHOD - A fragrance delivery device, system, and method of use and manufacturing are disclosed. The device has a vapor releasing membrane including a plurality of micropores, wherein each respective micropore has a consistent diameter dimension in both a delivery condition and in a use-condition of the fragrance delivery device. The device further includes a flexible impermeable barrier coupled to the vapor releasing membrane along a perimeter thereof, wherein the vapor releasing membrane and impermeable barrier define a cavity there between having a predetermined volume. A substance is disposed in the cavity up to the predetermined volume, the substance comprising a volatile fragrance disposed in a matrix, wherein the substance has a first viscosity in the delivery condition and a second viscosity in the use-condition, the volatile fragrance being releasable from the matrix when exposed to a predetermined temperature and emittable through the plurality of micropores. | 2019-10-10 |
20190307913 | SCENT DIFFUSER USING BOTTLE - A scent diffuser contains: a body, a power connection unit, a pump, and a diffusing device. The body includes an accommodation chamber and a first opening. The power connection unit is housed in the accommodation chamber. The pump includes an air inflow segment and an air outflow segment. The diffusing device is accommodated in the body and includes a cap, a nozzle, a spraying member, a holder, and a spray hose. The cap has a first orifice, a second orifice, and a third orifice. The spraying member has a receiving groove, a suction mouth, and an outlet. The nozzle has a shrinkage conduit and a narrow conduit, and a slit is defined between the nozzle of the diffusing device and the receiving groove of the spraying member. The holder has a connection portion, and the cap is coupled on the holder. | 2019-10-10 |
20190307914 | FLEXIBLE ION GENERATOR DEVICE - A flexible ion generator device that includes a dielectric layer having a first end, a second end, a first side, a second side, a top side, and a bottom side, at least one trace positioned on the dielectric layer and having a plurality of emitters engaged to the at least one trace, wherein the trace extends along the top side of the dielectric layer and along a substantially parallel plane with respect to either the first side or the second side and in predetermined locations periodically along the length of the dielectric layer, the at least one trace extends downwardly from the parallel plane for a distance and then upwardly towards the parallel plane. | 2019-10-10 |
20190307915 | Tissue-Adhesive Material - The invention is directed to a tissue-adhesive polymer blend comprising a bioresorbable carrier polymer and a bioresorbable synthetic tissue-reactive polymer as well as to a tissue-adhesive device for sealing dura mater comprising said tissue-adhesive polymer blend. | 2019-10-10 |
20190307916 | SELECTIVELY POLYMERIZABLE COMPOSITIONS AND METHODS OF USE IN VIVO - Otologic materials and methods are provided. For example, a cell-adhesive, biodegradable hydrogel scaffold loaded with time-released drugs for repairing chronic tympanic membrane perforations is disclosed, methods of making same and administering same are provided. This hydrogel may promote vascular in-growth and epithelial cell growth of the tympanic membrane with the purpose of closing the perforation and providing a barrier between the external and middle ear. The hydrogel is initially a liquid polymer that only gels upon exposure to specific conditions, such as exposure to light. This scaffold may simultaneously induce repair of the tympanic membrane while preventing or alleviating middle ear infection, thus filling a void in current tympanic membrane perforation therapies. | 2019-10-10 |
20190307917 | PLIABLE SILK MEDICAL DEVICE - An implantable, pliable silk device (e.g., in a form of a knitted mesh) for use in human soft tissue support and/or repair that provides stretch or pliable properties, e.g., multi-directional elongation properties. Such a device permits physicians or users to alter or manipulate the device dimension and/or shape at the time of device implantation, thereby permitting the device to conform to the contour of a target area or tissue more easily and providing more precise positioning of the device over the target area or tissue. In some embodiments, the implantable pliable silk device comprises a knit pattern feature that substantially prevents unraveling and preserves the stability of the mesh when cut. For example, the pliable silk device is a knitted mesh comprising at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes. | 2019-10-10 |
20190307918 | NEUROGENIC REGULATION OF BONE GROWTH AND BONE DEGRADATION - This disclosure relates to methods for promoting bone formation or reducing bone destruction. This disclosure also relates to methods for promoting the recruitment of mesenchymal stem cells (MSCs) to a local site of injury or surgical intervention in bone to promote healing. In addition, this disclosure relates to methods for reducing or preventing mineral formation or bone growth, or reducing bone mass. The methods disclosed herein are useful for treating conditions such as osteopetrosis or osteoradionecrosis. | 2019-10-10 |
20190307919 | COATING FOR ARTIFICIAL MUSCLES AND ACTUATORS - An actuator device that includes at least one fiber, and at least one first coating is disclosed. The first coating encloses the at least one fiber. The actuator device may include a plurality of fibers and/or a conducting material. The coatings may enclose the plurality of fibers, or each individual fiber. The coatings may provide moisture protection, UV protection, saline protection, and oxidation protection. The coating may be thermally and electrically conducting or insulating, depending on the specific function and environment of the actuator device. | 2019-10-10 |
20190307920 | Self-Securing Biological Tissue Graft - An example biological tissue graft includes a body formed from a flexible biological tissue, the body having a first end and a second end opposite the first end. The biological tissue graft also includes an aperture positioned in the second end of the body that is sized to receive the first end of the body therethrough. | 2019-10-10 |
20190307921 | LAMINATED TISSUE GRAFTS COMPOSED OF WHARTON'S JELLY AND METHODS OF MAKING AND USING THE SAME - Described herein are tissue grafts derived from the placenta with improved physical and biological properties. In one aspect, the tissue graft includes a first membrane comprising Wharton's jelly laminated with amnion, chorion, or a combination thereof. The presence of Wharton's jelly in the grafts enhances the performance of allograft amniotic-derived, caderivic allograft, xenograft, or alloplast soft tissue substitutes. | 2019-10-10 |
20190307922 | Cartilage Material Having Minimal Hypertrophy and Robust Integration Capacity, and Uses Therefor - A method is provided for producing a live cartilaginous material useful for implantation into a patient. A method of treating a patient comprising implanting a cartilaginous material prepared according to the provided method in an anatomical site in a patient also is provided. | 2019-10-10 |
20190307923 | Preparation and Applications of 3D Bioprinting Bioinks for Repair of Bone Defects, Based on Cellulose Nanofibrils Hydrogels with Natural or Synthetic Calcium Phosphate Particles - The present invention relates to preparation of bioink composed of cellulose nanofibril hydrogel with native or synthetic Calcium containing particles. The concentration of the calcium containing particles can be between 1% and 40% w/v. Such bioink can be 3D Bioprinted with or without human or animal cells. Coaxial needle can be used where cellulose nanofibril hydrogel filled with Calcium particles can be used as shell and another hydrogel based bioink mixed with cells can be used as core or opposite. Such 3D Bioprinted constructs exhibit high porosity due to shear thinning properties of cellulose nanofibrils which provides excellent printing fidelity. They also have excellent mechanical properties and are easily handled as large constructs for patient-specific bone cavities which need to be repaired. The porosity promotes vascularization which is crucial for oxygen and nutrient supply. The porosity also makes it possible for further recruitment of cells which accelerate bone healing process. Calcium containing particles can be isolated from autologous bone, allogenic bone or xenogeneic bone but can be also isolated from minerals or be prepared by synthesis. Preferable Calcium containing particles consist of β-tricalcium phosphate which is resorbable or natural bone powder, preferably of human or porcine origin. The particles described in the present invention have particle size smaller than 400 microns, or more preferably smaller than 200 microns, to make it possible to handle in printing nozzle without clogging and to obtain a good resolution. Cellulose nanofibrils can be produced by bacteria orbe isolated from plants. They can be neutral, charged or oxidized to be biodegradable. The bioink can be additionally supplemented by other biopolymers which provide crosslinking. Such biopolymers can be alginates, chitosans, modified hyaluronic acid or modified collagen derived biopolymers. | 2019-10-10 |
20190307924 | TEXTILE PRODUCTS HAVING SELECTIVELY APPLIED SEALANT OR COATING AND METHOD OF MANUFACTURE - A substantially fluid impermeable textile graft may be produced by selective application of a substantially water-soluble material or masking agent, and optionally selective removal of excess substantially water-soluble material, followed by the application of a substantially water-insoluble sealant. The inner surface of the graft includes a coating of the substantially water-soluble material thereon. The outer surface includes a coating of the substantially water-insoluble sealant disposed thereon. The tubular wall having the coating of the substantially water-insoluble sealant is, after curing thereof, substantially impermeable to liquid. The substantially water-soluble material is removed from the graft after the application of the substantially water-insoluble sealant. | 2019-10-10 |
20190307925 | POLYACRYLAMIDE HYDROGEL FOR USE IN THE PREVENTION AND/OR TREATMENT OF SYNOVITIS IN A MAMMAL - The present invention relates to a polyacrylamide hydrogel for use in prevention and/or treatment of synovitis or pain associated with synovitis in a mammal by formation of an extra layer to the synovial membrane i.e. a sub-synovial layer and a novel synovial lining layer. Synovitis may occur in association with arthritis, such as osteoarthritis or rheumatoid arthritis, lupus, or gout, and the mammal suffering from synovitis is a preferably a human, a racing animal or a companion animal. | 2019-10-10 |
20190307926 | IMPLANTABLE BIOMATERIALS HAVING FUNCTIONAL SURFACES - Implantable materials having defined patterns of affinity regions for binding endothelial cells and providing for directed endothelial cell migration across the surface of the material. The affinity regions include photochemically altered regions of a material surface and physical members patterned on the material surface that exhibit a greater affinity for endothelial cell binding and migration than the remaining regions of the material surface. | 2019-10-10 |
20190307927 | INTIMATE CARE LUBRICANT COMPOSITIONS AND METHODS FOR MAKING SAME - Silicone-in-water emulsions and methods for making same, are disclosed which are useful and effective as lubricants for use in intimate care applications, as a skin condition, as a surgical lubricant and/or as a carrier for an active topical pharmaceutical agent. In preferred examples, the emulsions of the present invention are flowable, have a viscosity of equal to or below about 15,000 centipoise (cP), and are stable upon storage for at least about 1 year. | 2019-10-10 |
20190307928 | POLYMERIC PATCH SCAFFOLDS FOR ARTICULAR CARTILAGE REGENERATION - A polymeric substrate for treating a chondral or osteochondral defect includes a polymeric sheet having a predetermined shape and size for placement over a chondral or osteochondral defect. The polymeric sheet defines suture openings therein that allow fixation of the polymeric scaffold. Characteristically, the polymeric sheet includes biocompatible polymer. A method for treating a subject having a chondral or osteochondral defect is also provided. | 2019-10-10 |
20190307929 | COMPOSITIONS AND METHODS FOR REDUCING NEOINTIMA FORMATION - Compositions, devices, grafts and methods for reducing or preventing anti-neointima following cardiovascular injuries and interventions are disclosed. The compositions, devices, and grafts typically include an effective amount of a CTP synthase 1 inhibitor to reduce proliferation of vascular smooth muscle cells, without substantial reducing the proliferation of endothelial cells. Methods of reducing neointima formation, accelerating re-endothelialization, and reducing restenosis in a subject using the compositions, devices, and grafts are also disclosed. | 2019-10-10 |
20190307930 | Method and Apparatus for a Stent with a Capped-Release Mechanism (CRM) - Disclosed and claimed is any one of long-dwelling body lumen apparatus, such as a catheter or stent (c/s), said c/s comprising: at least one lumen fittingly disposed within a tubular member; a scaffold circumferentially disposed around at least one of an outer surface of at least the tubular member; said scaffold radially extending for at least a portion of the length of the at least tubular member. Furthermore, the scaffold comprised of any one of a pattern of interlocking struts with individual well-like reservoirs disposed; each reservoir having a depth sufficient enough to house at least a first agent of any one of a chemical moiety, each of the reservoirs capped to form an enclosure; and wherein a delayed degradation of said cap results in a sudden release of the housed at least first agent. Any number of agents, reservoirs, and cap configurations may be possible. | 2019-10-10 |
20190307931 | A METHOD, ARRANGEMENT AND A USER INTERFACE FOR CONTROLLING COLLECTING FLUID FROM A PATIENT - A method and graphical user interface are disclosed for controlling collecting fluid from a patient. A graphical user interface in at least one first user interface element displays on a display unit information related to at least one first collection container connected to a first suction channel, and in at least one second user interface element displays information related to at least one second collection container connected to a second suction channel. Also information regarding fluid collected from a patient to at least one of the collection containers may be displayed in a third user interface element. | 2019-10-10 |
20190307932 | AN ASSEMBLY FOR COLLECTING FLUID DURING A MEDICAL OR A SURGICAL OPERATION - An assembly is disclosed for collecting fluid during a medical or a surgical operation. The assembly can include a canister having an openable lid and a collection liner. The collection liner can include a closed bag portion and an inlet for a collection container. The inlet has a first end and a second end, which opens into the bag portion. The bag portion is placed inside the canister. The first end of the inlet for a collection container extends from between the edge of the canister and the edge of the lid to the outside of the canister when the lid is closed. | 2019-10-10 |
20190307933 | ADAPTABLE WOUND DRAINAGE SYSTEM - Provided are drainage systems that may include a drainage manifold and may be suitable for draining fluid from a tissue site. The drainage manifold may include a plurality of elongate members having a moveable end that may be adapted to configure the drainage manifold to treat a uniquely shaped tissue site. The drainage manifold may be coupled to a drainage tube with a transitional connector to provide a drainage system capable of distributing reduced pressure to the tissue site to enhance the drainage of fluids. | 2019-10-10 |
20190307934 | SYSTEMS AND METHODS FOR CONTROLLING OPERATION OF A REDUCED PRESSURE THERAPY SYSTEM - Negative pressure wound therapy apparatuses and dressings, and systems and methods for operating such apparatuses for use with dressings are disclosed. In some embodiments, controlling the delivery of therapy can be based on monitoring and detecting various operating conditions. An apparatus can have a controller configured to monitor the duty cycle of a source of negative pressure and, based on the monitored duty cycle, determine whether a leak is present. The controller can be configured to provide an indication that a leak is present. For example, the controller can be configured to suspend and/or pause the delivery of therapy, and to restart the delivery of therapy due to a timeout, request from a user, etc. In addition, the controller can be configured to pause and/or restart the delivery of therapy upon a request from the user, such as in response to the user operating a switch. | 2019-10-10 |
20190307935 | ABDOMINAL DRESSING WITH MECHANISM FOR FASCIAL CLOSURE - A system for treating a deep abdominal wound. The system includes a wound dressing. The wound dressing includes a visceral-protective layer, a compressive layer, and a sealing layer. The visceral-protective layer is configured to be positioned in an open abdomen. The compressive layer is configured to be disposed proximate to the visceral-protective layer. The compressive layer includes a pattern of voids configured for anisotropic collapse of the compressive layer when under negative pressure. The sealing layer is configured to form a sealed space in the open abdomen. A negative pressure source configured to provide negative pressure to the compressive layer. | 2019-10-10 |
20190307936 | Agitator Unit for Use with a Blood Product Storage System and Blood Product Storage System - The present disclosure relates to an agitator unit for use with a blood product storage system, wherein the agitator unit has a movable compartment to receive blood products and a drive for movement of the compartment. The drive of the agitator unit has at least one motor and a gear system with at least one planetary gear unit, wherein the planetary gear unit has at least one planet wheel, which is eccentrically movable by means of the motor, and a planet disc, wherein the planet wheel is connected to the compartment by means of a spigot and rolls on an internal periphery of the planet disc, wherein the spigot is adjustable in its relative position. In addition, the disclosure relates to a modular blood product storage system with an agitator unit. | 2019-10-10 |
20190307937 | SURGICAL SYSTEM AND METHOD OF USE - A surgical system for use in establishing and maintaining an opening to an anatomical space of a body, the system comprising an obturator assembly having a cutting portion at a distal end and a cannula, the cannula being detachably coupled to the cutting portion and deployable into the anatomical space of a patient, the cannula comprises a locking portion, and a lengthwise extendable body; a valve assembly comprising a passage for receiving the cannula, a first end for coupling to a fluid extraction device and a second end for placement external and adjacent the anatomical space; a base comprising a plate for placement on a patient external and adjacent the anatomical space, the plate has an aperture configured for receiving the obturator assembly and coupling means located about the aperture for coupling with the valve assembly; and wherein, in use, the locking portion of the cannula is configured to be retained in the valve assembly with the extendable body extended into the anatomical space to facilitate a path for fluid extraction, and wherein the cannula comprises means for retaining the cannula in its extended state. | 2019-10-10 |
20190307938 | MULTI-INPUT SPEED RESPONSE ALGORITHM FOR A BLOOD PUMP - A method of responding to an adverse event associated with an implantable blood pump including detecting the adverse event, reducing a pump speed of the blood pump relative to a set pump speed in response to the detected adverse event, and determining whether at least one of a group consisting of the adverse event and a second adverse event is present following the reducing of the pump speed of the blood pump. If the at least one of the group consisting of the adverse event and a second adverse event is not present, the method includes increasing the pump speed to the set pump speed and if the at least one of the group consisting of the adverse event and a second adverse event is present while increasing the pump speed to the set pump speed, the method includes reducing the pump speed to a maximum safe operating speed. | 2019-10-10 |
20190307939 | GRAVITY FED DIALYSIS SYSTEMS AND METHODS - A gravity fed peritoneal dialysis (“PD”) machine includes: a frame configured to be set on a supporting surface; at least one load cell; a scale platform supported by the frame via the at least one load cell positioned between the frame and the scale platform; a drain container support in mechanical communication with and extending downwardly from the scale platform, the machine configured such that when the frame is set on the supporting surface, at least one fresh PD fluid supply container is supportable by the scale platform above the at least one load cell and at least one used PD fluid drain container is supportable by the drain container support below the at least one load cell, so that a combined weight of fresh PD fluid and used PD fluid may be sensed by the at least one load cell. | 2019-10-10 |
20190307940 | Apparatus for High-Throughput Rapid Trapping of Circulating Tumor Cells and Method for Purifying Circulating Tumor Cells - An apparatus for high-throughput rapid trapping and purifying of circulating tumor cells and a method for purifying circulating tumor cells, relating to the field of biotechnology. The apparatus for high-throughput rapid trapping of circulating tumor cells comprises: a filter module, the filter module comprises a filter, a filter membrane which is arranged inside the filter and sealed with an inner wall of the filter, and a negative pressure device; the negative pressure device is connected with an end of an outlet of the filter, and used for maintaining a negative pressure within the filter; when a negative pressure is maintained within the filter by the negative pressure device, the filter membrane is configured to trap circulating tumor cells, then stain and wash the trapped cells by using reagents which are automatically loaded by means of a reagent loading module. The apparatus may automatically control loading a sample liquid to the filter as well as the negative pressure device, such that the process in which the circulating tumor cells are trapped by using the filter membrane and then stained has the advantages of being highly automated and having a high throughput (which can be achieved by means of increasing the number of filters). | 2019-10-10 |
20190307941 | Y-CONNECTOR FOR BLOOD PROCESSING SYSTEM AND DISPOSABLE SET CONTAINING SAME - A tubing set for a blood processing system includes a first connector, a first tube, and a second tube. The first connector is configured to connect to a separation device within the blood processing system, and has a first inlet configured to be fluidly connected to an outlet of the separation device. The first connector also has an outlet and a second inlet. The first tube fluidly connects to the outlet and fluidly connects the separation device and a blood component storage container. The second tube is fluidly connected to the second inlet and fluidly connects the separation device and a saline storage container. The second tube may include a second connector that connects to the saline storage container. | 2019-10-10 |
20190307942 | COLD AND HEAT EXCHANGE SYSTEM FOR CARDIAC SURGICAL OPERATION WITH CARDIAC ARREST - A cold and heat exchange system for a cardiac surgical operation with cardiac arrest, comprising: an ice water tank ( | 2019-10-10 |
20190307943 | BLOOD PUMP SYSTEMS AND METHODS - The present invention relates to a rotary blood pump with a double pivot contact bearing system with an operating range between about 50 mL/min and about 1500 mL/min, wherein the force on the upper bearing is less than 3N during operating speeds up to 6000 rpm. The rotary blood pump is part of a blood pump system that includes blood conduit(s), a control system with optional sensors, and a power source. Embodiments of the present invention may include elements designed to increase the length of time the rotary blood system can operate effectively in vivo, including wear resistant bearing materials, a rotor back plate for magnetic attraction of the rotor to reduce bearing pivot bearing forces and wear, a rotor size and shape and a bearing gap that combine to create a hydrodynamic bearing effect and reduce bearing pivot bearing forces and wear, improved intravascular conduits with increased resistance to thrombosis, conduit insertion site cuffs to resist infection, and conduit side ports amenable to the easy insertion of guidewire and catheter-based medical devices to treat conduits and related blood vessels to maintain blood pump system function over time. | 2019-10-10 |
20190307944 | ACCESS CANNULA COMPRISING BLOCKING DEVICE - An access cannula includes a dwell tube that serves as an access during treatment. A blocking device maintains the dwell tube kinked in an idle position. | 2019-10-10 |
20190307945 | VASCULAR ISOLATION SYSTEMS AND METHODS - A system and method enabling the receipt of image data of a patient, identification of one or more locations within the image data depicting symptoms of lung disease, analyzing airways and vasculature proximate the identified locations, planning a pathway to the one or more locations, navigating an extended working channel to one of the locations, identifying the direction of blood flow within vasculature serving the location, positioning a catheter proximate the location, and temporarily isolating a portion of the identified vasculature serving the location depicting symptoms of lung disease. | 2019-10-10 |
20190307946 | ACOUSTIC SEPARATION FOR BIOPROCESSING - A method for separating cells in a biofluid includes pretreating the biofluid by introducing an additive comprising a cell activator, flowing the pretreated biofluid through a microfluidic separation channel, and applying acoustic energy to the microfluidic separation channel to accumulate target cells in a primary stream and non-target cells in a secondary stream. A system for microfluidic cell separation capable of separating target cells from non-target cells in a biofluid includes at least one microfluidic separation channel, a source of biofluid, a source of additive comprising a cell activator, and at least one acoustic transducer coupled to the microfluidic separation channel. | 2019-10-10 |
20190307947 | Dual Pump Arthroscopic Irrigation/Aspiration System With Outflow Control - A fluid pump system having a first fluid pump for pumping fluid from a source to a surgical site and a second fluid pump for removing fluid from the surgical site at a first predetermined rate, wherein said fluid pump system intermittently operates in conjunction with a surgical tool which, when operational, removes fluid from the surgical site at a second predetermined rate greater than said first predetermined rate, the improvement including a sensor for sensing a predetermined parameter of the surgical tool and providing an output signal indicating that the surgical tool is operating; and an actuating means responsive to said output signal to actuate said second fluid pump to remove fluid from the surgical site at second predetermined rate. | 2019-10-10 |
20190307948 | APPARATUS AND METHOD FOR PRODUCING AN ENRICHED MEDICAL CONTRAST SUSPENSION - A medical contrast suspension generating delivery apparatus includes a Venturi-agitating tip assembly, a source of pressurized medical carbon dioxide, a source of an iodinated contrast medium, and a dual lumen catheter connecting the Venturi-agitating tip assembly to the source of pressurized medical carbon dioxide and the source of the iodinated contrast medium. | 2019-10-10 |
20190307949 | INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS - Methods for setting up, maintaining and operating a radiopharmaceutical infusion system, that includes a radioisotope generator, are facilitated by a computer of the system. The computer may include pre-programmed instructions and a computer interface, for interaction with a user of the system, for example, in order to track contained volumes of eluant and/or eluate, and/or to track time from completion of an elution performed by the system, and/or to calculate one or more system and/or injection parameters for quality control, and/or to perform purges of the system, and/or to facilitate diagnostic imaging. | 2019-10-10 |
20190307950 | MICROFLOW RESTRICTOR ASSEMBLY AND METHODS OF MAKING THE SAME - A medical fluid microflow assembly having an assembly fluid inlet and an assembly fluid outlet, and a mandrel having a curved exterior surface, the mandrel being positioned within an cavity of a housing so that the exterior surface of the mandrel is substantially parallel to an interior surface of the cavity, and at least one protrusion positioned helically around and extending from the interior surface of the cavity, each protrusion abutting the exterior surface of the mandrel to form a sealed fluid channel which has a channel inlet positioned proximate to the assembly fluid inlet and a channel outlet positioned proximate to the assembly fluid outlet, the exterior surface of the mandrel and the interior surface of the cavity having a minimal or neutral triboelectric value with respect to a fluid. | 2019-10-10 |
20190307951 | Devices and Methods for Modulating Medium Delivery - Devices, systems and methods for controlling, regulating, altering, transforming or otherwise modulating the delivery of a substance to a delivery site. The devices, systems and methods optimize the delivery of the substance to an intended site, such as a vessel, vascular bed, organ and/or other corporeal structures, while reducing inadvertent introduction or reflux substance to other vessels, vascular beds, organs, and/or other structures, including systemic introduction. | 2019-10-10 |
20190307952 | SYSTEM AND METHOD FOR INDUCTIVELY CHARGING A MEDICAL DEVICE - Methods and systems are disclosed wherein temperature in a device such as an ambulatory infusion pump is monitored during inductive charging of the device such that temperature-sensitive contents or components, such as, for example, insulin, particular circuitry and/or other components are not damaged. Temperature can be monitored in the device at one or more locations during inductive charging. If the temperature breaches one or more predetermined thresholds and/or is rising at a rate greater than one or more predetermined thresholds, charging can be suspended or provided at reduced power to prevent the temperature from further rising and damaging the contents and/or components of the device. One or more alerts associated with these events may also be triggered so that the user is aware of the situation and may take corrective action. | 2019-10-10 |
20190307953 | CONTRAST HEATING SYSTEM WITH IN-LINE CONTRAST WARMER - A system for heating a medical fluid has at least one first fluid container for storing the fluid, a fluid injector having at least one second fluid container for receiving the fluid from the at least one first fluid container through a fluid path set, at least one heating element positioned in-line with the fluid path set between the at least one first fluid container and the at least one second fluid container of the fluid injector for heating the fluid to a pre-determined temperature as the fluid flows through at least one fluid path element, and a controller for controlling an output of the at least one heating element based on at least one of a property of the at least one heating element and a property of the fluid flowing through the at least one fluid path element. | 2019-10-10 |
20190307954 | Medicament Delivery Device - The present disclosure relates to a medicament delivery device comprising a medicament receiving element, at least one fluid chamber having a fluid outlet configured to direct fluid vapour towards the medicament receiving element, a heating element for heating the fluid in the at least one fluid chamber. The device is configured such that, in use, the heating element heats the fluid in the at least one fluid chamber to at least partially evaporate the fluid so that the vapor pressure in the at least one fluid chamber increases until the fluid is expelled out of the at least one fluid chamber through the fluid outlet towards the medicament receiving element and entrains the medicament towards the patient's skin. | 2019-10-10 |
20190307955 | Fluid Delivery Device Needle Retraction Mechanisms, Cartridges and Expandable Hydraulic Fluid Seals - A fluid delivery device includes an automatic needle retraction mechanism configured to automatically retract a delivery end of a needle into a housing. In one embodiment, the needle assembly is configured to automatically withdraw the delivery end of the needle into the housing upon an actuator moving from the first position to the second position. In one embodiment, the needle assembly is configured to automatically withdraw the delivery end of the needle into the housing upon decoupling a bottom surface of the housing from a skin surface. | 2019-10-10 |
20190307956 | INFUSION DEVICE CONSTITUTED TO DETECT AN ABNORMAL CONDITION DURING BOLUS INJECTION - Infusion device constituted to detect an abnormal condition during bolus injection An infusion device ( | 2019-10-10 |